Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15340958 | 0.85 | TSHR (0.49) | TSHRCYP3A4MAPTALDH1A1MEN1 | |
| SCHEMBL9069658 | 0.85 | ALDH1A1 (0.56) | TSHRCYP3A4MAPTALDH1A1MEN1 | |
| SCHEMBL15340917 | 0.85 | TSHR (0.54) | TSHRCYP3A4MAPTALDH1A1MEN1 | |
| SCHEMBL15330373 | 0.78 | ALDH1A1 (0.47) | TSHRCYP3A4MAPTALDH1A1MEN1 | |
| SCHEMBL15340971 | 0.78 | CYP3A4 (0.48) | TSHRCYP3A4ALDH1A1TDP1ALOX15 | |
| SCHEMBL15340938 | 0.75 | TSHR (0.54) | TSHRCYP3A4MAPTALDH1A1MEN1 | |
| SCHEMBL772636 | 0.75 | CD44 (0.54) | TSHRCYP3A4MAPTALDH1A1MEN1 | |
| SCHEMBL15329618 | 0.75 | MAPT (0.51) | TSHRCYP3A4MAPTALDH1A1MEN1 | |
| SCHEMBL12364210 | 0.75 | TDP1 (0.51) | TSHRCYP3A4MAPTALDH1A1MEN1 | |
| SCHEMBL98492 | 0.75 | TSHR (1.00) | TSHRCYP3A4MAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695129-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160251317-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL INC (US) | 2016-09-01 | — | — | US | disclosed |
| US-9000187-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130281392-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL LIMITED (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251317-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | LIPC, CYP3A43, CYP51A1 | TSHR 4248/4885CYP3A4 25/4885MAPT 4208/4885 |
| US-20130281392-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | LIPC, CYP3A43, CYP51A1 | TSHR 4248/4885CYP3A4 25/4885MAPT 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.